In vitro studies showed that mechanisms operating at the level of lymphocyte effector function and tumorigenicity were engaged in the presence of rshCD6, such as defective Treg generation and function, decreased CD166/ALCAM-mediated tumor cell proliferation/migration and impaired galectin-induced T-cell apoptosis [110]. Here, ALCAM is linked to neoplasm.